Lesley Portnoy and Food and Drug Administration

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altria Group, Inc. | Globe Newswire | 11/15/2019

… Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] , or visit our website at www.glancylaw.com . On December 20, 2018, Altria acquired a 35% stake in investment in JUUL Labs, Inc. (“JUUL”), the purported U.S. leader in electronic vapor products, including e-cigarettes. On April 3, 2019, the U.S. Food and Drug Administration (“FDA”) announced its investigation into nearly three dozen cases of people suffering …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against electroCore, Inc. | Globe Newswire | 11/8/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] … on September 25, 2019, the Company revealed that the U.S. Food and Drug Administration requested more information and analysis of clinical data for electroCore’s 510(k) submission, which seeks an expanded indication for the use …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Myriad Genetics, Inc. | Globe Newswire | 11/7/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] … Company revealed that, since at least late 2018, the U.S. Food and Drug Administration (“FDA”) had increasingly questioned the claims of marketed genetics tests, such as Myriad’s GeneSight. Myriad also disclosed that “the FDA requested …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against electroCore, Inc. | The Wapakoneta Daily News | 10/31/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] … on September 25, 2019, the Company revealed that the U.S. Food and Drug Administration requested more information and analysis of clinical data for electroCore’s 510(k) submission, which seeks an expanded indication for the use …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altria Group, Inc. | Benzinga | 10/29/2019

… Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] www.glancylaw.com . On December 20, 2018, Altria acquired a 35% stake in investment in JUUL Labs, Inc. (“JUUL”), the purported U.S. leader in electronic vapor products, including e-cigarettes. On April 3, 2019, the U.S. Food and Drug Administration (“FDA”) announced its investigation into nearly three dozen cases of people suffering from seizures after vaping. On …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altria Group, Inc. - GuruFocus.com | 10/29/2019

… Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] , or visit our website at www.glancylaw.com . On December 20, 2018, Altria acquired a 35% stake in investment in JUUL Labs, Inc. (“JUUL”), the purported U.S. leader in electronic vapor products, including e-cigarettes. On April 3, 2019, the U.S. Food and Drug Administration (“FDA”) announced its investigation into nearly three dozen cases of people suffering …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Myriad Genetics, Inc. | Benzinga | 10/22/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] … Company revealed that, since at least late 2018, the U.S. Food and Drug Administration (“FDA”) had increasingly questioned the claims of marketed genetics tests, such as Myriad’s GeneSight. Myriad also disclosed that “the FDA requested …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Myriad Genetics, Inc. - GuruFocus.com | 10/22/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected … Company revealed that, since at least late 2018, the U.S. Food and Drug Administration (“FDA”) had increasingly questioned the claims of marketed genetics tests, such as Myriad’s GeneSight. Myriad also disclosed that “the FDA requested …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against electroCore, Inc. - GuruFocus.com | 10/22/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected … on September 25, 2019, the Company revealed that the U.S. Food and Drug Administration requested more information and analysis of clinical data for electroCore’s 510(k) submission, which seeks an expanded indication for the use …

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Altria Group, Inc. Investors | Business Wire | 10/7/2019

Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] , or visit our website at www.glancylaw.com . On December 20, 2018, Altria acquired a 35% stake in investment in JUUL Labs, Inc. (“JUUL”), the purported U.S. leader in electronic vapor products, including e-cigarettes. On April 3, 2019, the U.S. Food and Drug Administration (“FDA”) announced its investigation into nearly three dozen cases of people suffering …

Glancy Prongay & Murray LLP Announces Investigation on Behalf of Altria Group, Inc. Investors | Business Wire | 10/4/2019

Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] , or visit our website at www.glancylaw.com . On December 20, 2018, Altria acquired a 35% stake in investment in JUUL Labs, Inc. (“JUUL”), the purported U.S. leader in electronic vapor products, including e-cigarettes. On April 3, 2019, the U.S. Food and Drug Administration (“FDA”) announced its investigation into nearly three dozen cases of people suffering …

Glancy Prongay & Murray LLP Announces Investigation on Behalf of Altria Group, Inc. Investors – Company Announcement - FT.com | Financial Times | 10/4/2019

… Lesley Portnoy, Esquire , at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] , or visit our website at www.glancylaw.com . On December 20, 2018 , Altria acquired a 35% stake in investment in JUUL Labs, Inc. (“JUUL”), the purported U.S. leader in electronic vapor products, including e-cigarettes. On April 3, 2019 , the U.S. Food and Drug Administration (“FDA”) announced its investigation into nearly three dozen cases of people suffering …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against electroCore, Inc. | Business Wire | 10/2/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] … on September 25, 2019, the Company revealed that the U.S. Food and Drug Administration requested more information and analysis of clinical data for electroCore’s 510(k) submission, which seeks an expanded indication for the use …

Glancy Prongay & Murray LLP Files Securities Class Action on Behalf of electroCore, Inc. Investors – Company Announcement - FT.com | Financial Times | 9/27/2019

… per share on May 15, 2019 , thereby injuring investors. Then, on September 25, 2019 , the Company revealed that the U.S. Food and Drug Administration requested more information and analysis of clinical data for electroCore’s 510 … rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire , of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Curaleaf Holdings, Inc. | Globe Newswire | 9/26/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] … conduct would result in a warning letter from the U.S. Food and Drug Administration (“FDA”); and (4) that as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Curaleaf Holdings, Inc. - Business Wire | 8/14/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to , or visit … conduct would result in a warning letter from the U.S. Food and Drug Administration (“FDA”); and (4) that as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and …

Glancy Prongay & Murray LLP Announces Investigation on Behalf of Novartis AG Investors (NVS) | Business Wire | 8/8/2019

Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] , or visit our website at www.glancylaw.com . On August 6, 2019, the U.S. Food and Drug Administration (“FDA”) issued a statement revealing that data submitted in the Company’s biologics license application (“BLA”) for its gene therapy drug, Zolgensma, had been manipulated. Moreover, it stated that the Company “became aware of the issue of the data manipulation …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc. – Company Announcement - FT.com | Financial Times | 8/3/2019

Lesley Portnoy, Esquire , at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] , or visit our website at www.glancylaw.com . On February 22, 2019 , the U.S. Food and Drug Administration (“FDA”) released a briefing document which contradicted the Company’s assertions that its treatment selinexor was “well-tolerated” by patients. Specifically, the FDA revealed that a previous trial of the Company’s selinexor yielded “worse overall survival” and concluded that selinexor …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Karyopharm Therapeutics, Inc. | Business Wire | 8/2/2019

Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] , or visit our website at www.glancylaw.com . On February 22, 2019, the U.S. Food and Drug Administration (“FDA”) released a briefing document which contradicted the Company’s assertions that its treatment selinexor was “well-tolerated” by patients. Specifically, the FDA revealed that a previous trial of the Company’s selinexor yielded “worse overall survival” and concluded that selinexor …

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Karyopharm Therapeutics, Inc. Investors | Business Wire | 7/27/2019

Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] , or visit our website at www.glancylaw.com . On February 22, 2019, the U.S. Food and Drug Administration (“FDA”) released a briefing document which contradicted the Company’s assertions that its treatment selinexor was “well-tolerated” by patients. Specifically, the FDA revealed that a previous trial of the Company’s selinexor yielded “worse overall survival” and concluded that selinexor …

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Karyopharm Therapeutics, Inc. Investors – Company Announcement - FT.com | Financial Times | 7/27/2019

Lesley Portnoy, Esquire , at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] , or visit our website at www.glancylaw.com . On February 22, 2019 , the U.S. Food and Drug Administration (“FDA”) released a briefing document which contradicted the Company’s assertions that its treatment selinexor was “well-tolerated” by patients. Specifically, the FDA revealed that a previous trial of the Company’s selinexor yielded “worse overall survival” and concluded that selinexor …

Glancy Prongay & Murray LLP Announces Investigation on Behalf of Karyopharm Therapeutics, Inc. Investors (KPTI) | Business Wire | 7/26/2019

Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] , or visit our website at www.glancylaw.com . On February 22, 2019, the U.S. Food and Drug Administration (“FDA”) released a briefing document which contradicted the Company’s assertions that its treatment selinexor was “well-tolerated” by patients. Specifically, the FDA revealed that a previous trial of the Company’s selinexor yielded “worse overall survival” and concluded that selinexor …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Helius Medical Technologies, Inc. | Business Wire | 7/16/2019

Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] , or visit our website at www.glancylaw.com . On January 25, 2019, the Company announced that it had received a request for additional data and information from the U.S. Food and Drug Administration (the “FDA”) related to the Company’s request for de novo classification and 510(k) clearance of its Portable Neuromodulation Stimulator (PoNS™) device. On this …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acer Therapeutics Inc. | Business Wire | 7/16/2019

Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] , or visit our website at www.glancylaw.com . On June 25, 2019, the Company revealed a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration regarding its marketing application for EDSIVO, a medication for the treatment of Ehlers-Danlos syndrome. According to the CRL, “an adequate and well-controlled trial” was required to determine whether …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acer Therapeutics Inc. - Yahoo Finance | Yahoo News | 7/16/2019

Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to , or visit our website at www.glancylaw.com . On June 25, 2019, the Company revealed a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration regarding its marketing application for EDSIVO, a medication for the treatment of Ehlers-Danlos syndrome. According to the CRL, “an adequate and well-controlled trial” was required to determine whether EDSIVO “reduces …